Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process

NICE Accredited

Barrett's Dysplasia Cancer Task Force - BADCAT
Barrett’s Dysplasia Cancer Task Force (BADCAT)
Publication date:
24 April 2012


Esophageal adenocarcinoma (EA) is increasingly common among patients with Barrett's esophagus (BE). This guideline aims to provide consensus recommendations based on the medical literature that clinicians could use to manage patients with BE and low-grade dysplasia, high-grade dysplasia (HGD), or early-stage EA.